Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, Westwood JA, Sandhu S, Raleigh JM, Behren A, Cebon J, Darcy PK, Kershaw MH, McArthur GA, Gyorki DE, Neeson PJ.

Sci Rep. 2018 Jul 24;8(1):11158. doi: 10.1038/s41598-018-28944-3.

2.

An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy.

Westwood JA, Ellis S, Danne J, Johnson C, Oorschot V, Ramm G, Tscharke DC, Davenport AJ, Whisstock JC, Darcy PK, Kershaw MH, Slaney CY.

Oncotarget. 2017 Dec 14;8(70):115215-115229. doi: 10.18632/oncotarget.23215. eCollection 2017 Dec 29.

3.

Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.

Pereira-Salgado A, Westwood JA, Russell L, Ugalde A, Ortlepp B, Seymour JF, Butow P, Cavedon L, Ong K, Aranda S, Breen S, Kirsa S, Dunlevie A, Schofield P.

JMIR Mhealth Uhealth. 2017 Dec 6;5(12):e184. doi: 10.2196/mhealth.8349.

4.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

5.

Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice.

Yong CS, Westwood JA, Schröder J, Papenfuss AT, von Scheidt B, Moeller M, Devaud C, Darcy PK, Kershaw MH.

PLoS One. 2015 Oct 27;10(10):e0140543. doi: 10.1371/journal.pone.0140543. eCollection 2015.

6.

Cross-talk between tumors can affect responses to therapy.

Devaud C, John LB, Westwood JA, Yong CS, Beavis PA, Schwendener RA, Darcy PK, Kershaw MH.

Oncoimmunology. 2015 Jun 17;4(7):e975572. eCollection 2015 Jul.

7.

Erratum to: Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment.

Russell L, Gough K, Drosdowsky A, Schofield P, Aranda S, Butow PN, Westwood JA, Krishnasamy M, Young JM, Phipps-Nelson J, King D, Jefford M.

J Cancer Surviv. 2015 Sep;9(3):471. doi: 10.1007/s11764-015-0455-x. No abstract available.

PMID:
25971369
8.

Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Devaud C, Westwood JA, Teng MW, John LB, Yong CS, Duong CP, Smyth MJ, Darcy PK, Kershaw MH.

Oncoimmunology. 2014 Dec 21;3(11):e963395. eCollection 2014 Nov.

9.

The potential impact of mouse model selection in preclinical evaluation of cancer immunotherapy.

Westwood JA, Darcy PK, Kershaw MH.

Oncoimmunology. 2014 Jul 3;3(7):e946361. eCollection 2014.

10.

Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment.

Russell L, Gough K, Drosdowsky A, Schofield P, Aranda S, Butow PN, Westwood JA, Krishnasamy M, Young JM, Phipps-Nelson J, King D, Jefford M.

J Cancer Surviv. 2015 Sep;9(3):462-70. doi: 10.1007/s11764-014-0422-y. Epub 2015 Jan 9. Erratum in: J Cancer Surviv. 2015 Sep;9(3):471.

PMID:
25573722
11.

Clinical application of genetically modified T cells in cancer therapy.

Kershaw MH, Westwood JA, Slaney CY, Darcy PK.

Clin Transl Immunology. 2014 May 16;3(5):e16. doi: 10.1038/cti.2014.7. eCollection 2014 May. Review.

12.

Foxp3 expression in macrophages associated with RENCA tumors in mice.

Devaud C, Yong CS, John LB, Westwood JA, Duong CP, House CM, Denoyer D, Li J, Darcy PK, Kershaw MH.

PLoS One. 2014 Sep 29;9(9):e108670. doi: 10.1371/journal.pone.0108670. eCollection 2014.

13.

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.

Westwood JA, Matthews GM, Shortt J, Faulkner D, Pegram HJ, Duong CP, Chesi M, Bergsagel PL, Sharp LL, Huhn RD, Darcy PK, Johnstone RW, Kershaw MH.

Leuk Res. 2014 Aug;38(8):948-54. doi: 10.1016/j.leukres.2014.05.010. Epub 2014 Jun 2.

PMID:
24934848
14.

Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice.

Westwood JA, Potdevin Hunnam TC, Pegram HJ, Hicks RJ, Darcy PK, Kershaw MH.

PLoS One. 2014 May 2;9(5):e95847. doi: 10.1371/journal.pone.0095847. eCollection 2014.

15.

Environmental enrichment does not impact on tumor growth in mice.

Westwood JA, Darcy PK, Kershaw MH.

F1000Res. 2013 Jun 12;2:140. doi: 10.12688/f1000research.2-140.v1. eCollection 2013.

16.

Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment.

Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK.

Oncoimmunology. 2013 Sep 1;2(9):e25962. Epub 2013 Aug 2. Review.

17.

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.

Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH.

Oncoimmunology. 2013 Aug 1;2(8):e25961. Epub 2013 Aug 22. Review.

18.

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ, Darcy PK, Kershaw MH.

Mol Ther. 2014 Jan;22(1):18-27. doi: 10.1038/mt.2013.219. Epub 2013 Sep 19.

19.

Gene-engineered T cells for cancer therapy.

Kershaw MH, Westwood JA, Darcy PK.

Nat Rev Cancer. 2013 Aug;13(8):525-41. doi: 10.1038/nrc3565. Review.

PMID:
23880905
20.

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westwood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM.

Mol Ther. 2013 Nov;21(11):2122-9. doi: 10.1038/mt.2013.154. Epub 2013 Jul 8.

21.

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.

Henderson MA, Yong CS, Duong CP, Davenport AJ, John LB, Devaud C, Neeson P, Westwood JA, Darcy PK, Kershaw MH.

Immunotherapy. 2013 Jun;5(6):577-90. doi: 10.2217/imt.13.37.

PMID:
23725282
22.

Engineering T cell function using chimeric antigen receptors identified using a DNA library approach.

Duong CP, Westwood JA, Yong CS, Murphy A, Devaud C, John LB, Darcy PK, Kershaw MH.

PLoS One. 2013 May 7;8(5):e63037. doi: 10.1371/journal.pone.0063037. Print 2013.

23.

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.

John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2012 Apr 1;72(7):1651-60. doi: 10.1158/0008-5472.CAN-11-2788. Epub 2012 Feb 7.

24.

Autoimmunity associated with immunotherapy of cancer.

Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH.

Blood. 2011 Jul 21;118(3):499-509. doi: 10.1182/blood-2011-01-325266. Epub 2011 Apr 29. Review. Erratum in: Blood. 2012 Dec 20;120(26):5251.

PMID:
21531979
25.

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.

Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH.

Cancer Immunol Immunother. 2011 May;60(5):671-83. doi: 10.1007/s00262-011-0984-8. Epub 2011 Feb 16.

26.

Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.

Duong CP, Westwood JA, Berry LJ, Darcy PK, Kershaw MH.

Immunotherapy. 2011 Jan;3(1):33-48. doi: 10.2217/imt.10.81.

PMID:
21174556
27.

Tumor ablation by gene-modified T cells in the absence of autoimmunity.

Wang LX, Westwood JA, Moeller M, Duong CP, Wei WZ, Malaterre J, Trapani JA, Neeson P, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2010 Dec 1;70(23):9591-8. doi: 10.1158/0008-5472.CAN-10-2884. Epub 2010 Nov 23.

28.

Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.

Westwood JA, Darcy PK, Guru PM, Sharkey J, Pegram HJ, Amos SM, Smyth MJ, Kershaw MH.

J Transl Med. 2010 Apr 28;8:42. doi: 10.1186/1479-5876-8-42.

29.

Genetic redirection of T cells for cancer therapy.

Westwood JA, Kershaw MH.

J Leukoc Biol. 2010 May;87(5):791-803. doi: 10.1189/jlb.1209824. Epub 2010 Feb 23. Review.

PMID:
20179152
30.

Enhancing adoptive immunotherapy of cancer.

Westwood JA, Berry LJ, Wang LX, Duong CP, Pegram HJ, Darcy PK, Kershaw MH.

Expert Opin Biol Ther. 2010 Apr;10(4):531-45. doi: 10.1517/14712591003610622. Review.

PMID:
20132063
31.

Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice.

Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, Smyth MJ, Darcy PK, Kershaw MH.

Clin Cancer Res. 2009 Dec 15;15(24):7624-7633.

32.

The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.

Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, Ball D, Michael M, Burman A, Mayura-Guru P, Trapani JA, Peinert S, Hönemann D, Miles Prince H, Scott AM, Smyth MJ, Darcy PK, Kershaw MH.

J Immunother. 2009 Apr;32(3):292-301. doi: 10.1097/CJI.0b013e31819b7c8e.

PMID:
19242371
33.

Perforin-mediated suppression of B-cell lymphoma.

Bolitho P, Street SE, Westwood JA, Edelmann W, Macgregor D, Waring P, Murray WK, Godfrey DI, Trapani JA, Johnstone RW, Smyth MJ.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2723-8. doi: 10.1073/pnas.0809008106. Epub 2009 Feb 5.

34.

Interleukin 21 enhances antibody-mediated tumor rejection.

Smyth MJ, Teng MW, Sharkey J, Westwood JA, Haynes NM, Yagita H, Takeda K, Sivakumar PV, Kershaw MH.

Cancer Res. 2008 Apr 15;68(8):3019-25. doi: 10.1158/0008-5472.CAN-07-6019.

35.

Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.

Westwood JA, Murray WK, Trivett M, Shin A, Neeson P, MacGregor DP, Haynes NM, Trapani JA, Mayura-Guru P, Fox S, Peinert S, Honemann D, Prince HM, Ritchie D, Scott AM, Smyth FE, Smyth MJ, Darcy PK, Kershaw MH.

Gene Ther. 2008 Jul;15(14):1056-66. doi: 10.1038/gt.2008.47. Epub 2008 Mar 27.

PMID:
18369322
36.

Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.

Moeller M, Kershaw MH, Cameron R, Westwood JA, Trapani JA, Smyth MJ, Darcy PK.

Cancer Res. 2007 Dec 1;67(23):11428-37.

37.

Combined natural killer T-cell based immunotherapy eradicates established tumors in mice.

Teng MW, Westwood JA, Darcy PK, Sharkey J, Tsuji M, Franck RW, Porcelli SA, Besra GS, Takeda K, Yagita H, Kershaw MH, Smyth MJ.

Cancer Res. 2007 Aug 1;67(15):7495-504.

38.

Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma.

Street SE, Zerafa N, Iezzi M, Westwood JA, Stagg J, Musiani P, Smyth MJ.

Cancer Res. 2007 Jun 1;67(11):5454-60.

39.

Antitumor activity of dual-specific T cells and influenza virus.

Murphy A, Westwood JA, Brown LE, Teng MW, Moeller M, Xu Y, Smyth MJ, Hwu P, Darcy PK, Kershaw MH.

Cancer Gene Ther. 2007 May;14(5):499-508. Epub 2007 Mar 2.

PMID:
17332777
40.

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15.

41.

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Hönemann D, Prince HM, Darcy PK, Kershaw MH.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19051-6. Epub 2005 Dec 19.

42.

Cutting edge: TRAIL deficiency accelerates hematological malignancies.

Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, Smyth MJ.

J Immunol. 2005 Nov 1;175(9):5586-90.

43.

Gene modification strategies to induce tumor immunity.

Murphy A, Westwood JA, Teng MW, Moeller M, Darcy PK, Kershaw MH.

Immunity. 2005 Apr;22(4):403-14. Review.

44.

Activation of NK cell cytotoxicity.

Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, van Dommelen SL, Degli-Esposti MA, Hayakawa Y.

Mol Immunol. 2005 Feb;42(4):501-10. Review.

PMID:
15607806
45.

Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.

Westwood JA, Kelly JM, Tanner JE, Kershaw MH, Smyth MJ, Hayakawa Y.

J Immunol. 2004 Jan 15;172(2):757-61.

46.

Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.

Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P.

Hum Gene Ther. 2002 Nov 1;13(16):1971-80.

PMID:
12427307
47.

Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.

Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, Raulet D, Smyth MJ.

J Immunol. 2002 Nov 15;169(10):5377-81.

48.

Dual-specific T cells combine proliferation and antitumor activity.

Kershaw MH, Westwood JA, Hwu P.

Nat Biotechnol. 2002 Dec;20(12):1221-7. Epub 2002 Nov 4.

PMID:
12415288
49.

Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.

Marroquin CE, Westwood JA, Lapointe R, Mixon A, Wunderlich JR, Caron D, Rosenberg SA, Hwu P.

J Immunother. 2002 May-Jun;25(3):278-88.

50.

Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature.

Kershaw MH, Westwood JA, Zhu Z, Witte L, Libutti SK, Hwu P.

Hum Gene Ther. 2000 Dec 10;11(18):2445-52.

PMID:
11119416

Supplemental Content

Loading ...
Support Center